|
|
|
|
|
|
|
|
Abstract
Aims
The
clinical course of patients with low-grade serous carcinoma (LGSC) can
be substantially different. The purpose of this study was to explore
whether molecular or pathological features could identify patients that
follow a more aggressive course.
Conclusion
Despite
limited case numbers, it appears that current molecular testing is
inferior in predicting outcome of LGSCs compared to a pathological
parameter or protein expression. Prediction of outcome based on the
primary tumour may be confounded by additional acquired changes over
time.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.